Teva's Opioid Vantrela: Conflicting Data On Oral Abuse Deterrence
This article was originally published in The Pink Sheet Daily
Executive Summary
Human abuse liking study, in vitro data paint different pictures of potential for hydrocodone extended-release product to deter oral abuse, FDA says ahead of advisory committee review; agency finds support for abuse-deterrent claims for intranasal, intravenous use.